<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>sinovacproforma.txt
<DESCRIPTION>SINOVAC BIOTECH 6K, PRO FORMA FINANCIALS
<TEXT>


EXHIBIT 99.2
------------














SINOVAC BIOTECH LTD.
--------------------
(formerly Net-Force Systems Inc.)

(Unaudited - Prepared by Management)

Pro-forma Consolidated Financial Statements

June 30, 2003







Index
-----

Pro-forma Consolidated Balance Sheet

Pro-Forma Consolidated Statement of Stockholders' Equity

Pro-Forma Consolidated Statement of Operations

Notes to Pro-forma Consolidated Financial Statements


















                                       F-1
<PAGE>



<TABLE>
<CAPTION>
SINOVAC BIOTECH LTD.
--------------------
(formerly Net-Force Systems Inc.)

Pro-forma Consolidated Balance Sheet
June 30, 2003
(Unaudited - Prepared by Management)
(Expressed in U.S. Dollars)
==================================================================================================================================
                                                               Sinovac       Tangshan Yian
                                                          Biotech Ltd.          Biological
                                                         June 30, 2003    Engineering Co.,           Pro-forma
                                                           (Pro-forma)       Ltd., June 30         adjustments          Pro-forma
                                                              (Note 1)                2003            (Note 3)        consolidated
----------------------------------------------------------------------------------------------------------------------------------

ASSETS

<S>                                                   <C>                      <C>            <C>                 <C>
Current assets
  Cash and cash equivalents                                  730,250      $       17,263 (a)  $      760,000      $    1,507,513
  Accounts receivable, net                                 1,020,096              28,785                   -           1,048,881
  Inventories                                              1,552,210              81,475                   -           1,633,685
  Prepaid expenses and deposits                               12,990                   -                   -              12,990
----------------------------------------------------------------------------------------------------------------------------------

Total current assets                                       3,315,546             127,523             760,000           4,203,069
----------------------------------------------------------------------------------------------------------------------------------

Property, plant and equipment                              7,706,783           1,894,958                               9,601,741
Due from a related party                                     677,487                   - (b)       1,800,000           1,800,000
                                                                                         (e)        (677,487)
Promissory note - secured, bearing interest at 8%                  -                   - (a)       1,793,996           1,793,996
Licenses, permits and other intangible asset               2,578,345                   -                   -           2,578,345
Investment in Sinovac Biotech Co., Ltd.                            -             532,139 (b)        (532,139)                  -
----------------------------------------------------------------------------------------------------------------------------------

Total assets                                          $   14,278,161           2,554,620      $    3,144,370      $   19,977,151
==================================================================================================================================

LIABILITIES

Current liabilities                                                -
  Loans payable                                              872,282           1,119,324 (c)  $   (1,119,324)     $      872,282
  Accounts payable and accrued liabilities                 1,760,714             705,990 (d)       2,200,000           4,666,704
  Due to related parties                                   1,246,344             677,487 (e)        (677,487)          1,246,344
  Deferred research grants                                   121,850                   -                   -             121,850
----------------------------------------------------------------------------------------------------------------------------------

Total current liabilities                                  4,001,190           2,502,801             403,189           6,907,180
----------------------------------------------------------------------------------------------------------------------------------

Unamortized finance charge on proceeds
  receivable on disposal of investment                             -                   - (b)         133,000             133,000

MINORITY INTEREST                                          5,035,667                   -                   -           5,035,667

STOCKHOLDERS' EQUITY

Preferred stock                                                    -                   -                   -                   -
  Authorized: 50,000,000 shares at par value of
    $0.001 each
  Issued and outstanding: nil
Common stock                                                  27,091           1,130,198 (a)       2,553,996              30,591
  Authorized: 100,000,000 shares at par value of
    $0.001 each                                                                          (c)       1,119,324
  Issued and outstanding: 30,591,033                                                     (d)      (4,800,018)

Additional paid-in capital                                 5,621,362              85,176 (d)       2,571,324           8,277,862
                                                                                                           -
Accumulated deficit                                         (407,149)         (1,163,555)(b)       1,134,861            (407,149)
                                                                                         (d)          28,694
----------------------------------------------------------------------------------------------------------------------------------

Total stockholders' equity                                 5,241,304              51,819           2,608,181           7,901,304
----------------------------------------------------------------------------------------------------------------------------------

                                                          14,278,161           2,554,620      $    3,144,370      $   19,977,151
==================================================================================================================================
</TABLE>

The accompanying notes are an integral part of these financial statements.


                                       F-2
<PAGE>



<TABLE>
<CAPTION>
SINOVAC BIOTECH LTD.
--------------------
(formerly Net-Force Systems Inc.)

Pro-forma Consolidated Statement of Stockholders' Equity
For the six months ended June 30, 2003
(Unaudited - Prepared by Management)
(Expressed in U.S. Dollars)
======================================================================================================================
                                                                                                                Total
                                                     Common stock             Additional                        Stock-
                                              ---------------------------        paid-in    Accumulated       holders'
                                                    Shares         Amount        capital        deficit         equity
----------------------------------------------------------------------------------------------------------------------


<S>                                            <C>           <C>            <C>            <C>            <C>
Recapitalization as a result of acquisition
  of China Sinovac by Sinovac (Pro-forma)      27,091,033    $    27,091    $ 5,621,362    $  (341,505)   $ 5,306,948

Issuance of common stock to effect
  the acquisition of Tangshan Yian              3,500,000          3,500      2,656,500              -      2,660,000

Comprehensive income (loss)
- Net (loss) for the period                             -              -              -        (65,644)       (65,644)
----------------------------------------------------------------------------------------------------------------------

Balance, June 30, 2003                         30,591,033    $    30,591    $ 8,277,862    $  (407,149)   $ 7,901,304
======================================================================================================================
</TABLE>

The accompanying notes are an integral part of these financial statements.
















                                       F-3
<PAGE>



<TABLE>
<CAPTION>
SINOVAC BIOTECH LTD.
--------------------
(formerly Net-Force Systems Inc.)

Pro-Forma Consolidated Statement of Operations
(Unaudited - Prepared by Management)
(Expressed in U.S. Dollars)
==============================================================================================================================
                                                           Sinovac       Tangshan Yian
                                                      Biotech Ltd.          Biological           Pro-forma
                                                        (Proforma)         Engineering         adjustments           Pro-forma
                                                          (Note 1)           Co., Ltd.            (Note 3)        Consolidated
------------------------------------------------------------------------------------------------------------------------------

                                                        Six months          Six months
                                                             Ended               Ended
                                                           June 30             June 30
                                                              2003                2003
------------------------------------------------------------------------------------------------------------------------------

<S>                                               <C>                         <C>         <C>                 <C>
Sales                                             $    1,090,856              21,903 (d)  $      (21,903)     $    1,090,856

Cost of sales                                            357,386              31,798 (d)         (31,798)            357,386
------------------------------------------------------------------------------------------------------------------------------

Gross profit (loss)                                      733,470              (9,895)              9,895             733,470
------------------------------------------------------------------------------------------------------------------------------

Selling, general and administrative expenses             615,615              53,451 (d)         (53,451)            615,615

Research and development expenses                         18,099                 365 (d)            (365)             18,099

Interest and financing expenses                          118,690              21,955 (d)         (21,955)            118,690

Depreciation of property, plant and equipment
  and amortization of licenses and permits               132,994              10,812 (d)         (10,812)            132,994

Equity in net loss of Sinovac                                  -              24,134 (d)         (24,134)                  -
------------------------------------------------------------------------------------------------------------------------------

                                                         885,398             110,717            (110,717)            885,398
------------------------------------------------------------------------------------------------------------------------------

Operating (loss)                                       (151,928)            (120,612)            120,612            (151,928)

Gain on disposal of drug license                               -             240,618 (d)        (240,618)                  -

Dilution gain                                                  -              98,698 (d)         (98,698)                  -

Gain on disposal of investment                                 -                   - (b)       1,134,861                   -
                                                                                     (d)      (1,134,861)
Interest income                                           23,214               1,101 (d)          (1,101)             23,214
------------------------------------------------------------------------------------------------------------------------------

Income (loss) for the period before income
  taxes and minority interest                          (128,714)             219,805            (219,805)           (128,714)

Deferred income tax (expense)                                  -            (47,930) (d)          47,930                   -

Minority interest                                         63,070                   -                   -              63,070
------------------------------------------------------------------------------------------------------------------------------

Net income (loss) for the period                  $      (65,644)            171,875      $     (171,875)     $      (65,644)
==============================================================================================================================
</TABLE>

The accompanying notes are an integral part of these financial statements.




                                       F-4
<PAGE>



SINOVAC BIOTECH LTD.
--------------------
(formerly Net-Force Systems Inc.)

Notes to Pro-forma Consolidated Financial Statements
June 30, 2003
(Unaudited - Prepared by Management)
(Expressed in U.S. Dollars)
================================================================================


1.   Basis of Presentation
--------------------------

     These pro-forma consolidated financial statements have been prepared solely
     for submission to the U.S. Securities and Exchange Commission in connection
     with the  acquisition  of Tangshan Yian  Biological  Engineering  Co., Ltd.
     ("Tangshan  Yian"),  a company  incorporated  in China and  engaged  in the
     research and development,  production and sales of pharmaceutical  products
     in China,  by Sinovac  Biotech Ltd.  ("Sinovac").  A major  shareholder and
     director  of  Sinovac  is also a director  and a  minority  shareholder  of
     Tangshan Yian.

     These  pro-forma  consolidated  financial  statements  are not  necessarily
     indicative  of the actual  results  which would have been  attained had the
     combination  been in effect on the date  indicated or which may be attained
     in the future.

     These  pro-forma  consolidated  financial  statements have been prepared by
     management  from  information  derived  from  the  pro-forma   consolidated
     financial  statements of Sinovac as at June 30, 2003 (after the  completion
     of its acquisition of Sinovac Biotech Co., Ltd.) and the audited  financial
     statements of Tangshan Yian as at June 30, 2003.


2.   Proposed Acquisition and Pro-forma Assumptions
---------------------------------------------------

     (a)  Letter Of Intent

          Pursuant to a letter of intent dated  October 20,  2003,  Sinovac will
          acquire 100%  interest in Tangshan  Yian by issuing  3,500,000  common
          stocks and paying $2.2 Million in cash, with a total  approximate fair
          value of $4.8  Million,  within  twelve  (12)  months from the date of
          entering into a formal agreement. The acquisition is recorded by using
          the purchase method of accounting.

     (b)  Disposal Of Long-term Investment

          On September 24, 2003,  Tangshan Yian disposed all of its 16% interest
          in Sinovac Biotech Co, Ltd. ("China Sinovac"),  a 51% owned subsidiary
          of Sinovac,  to an individual related to a common director of Tangshan
          Yian  and  China  Sinovac  for  cash of  approximately  $1.8  Million.
          Thangshan  Yian also agreed  that the  proceeds do not have to be paid
          until one year after the completion of this transaction.

          The  disposition  is assumed to have taken effect on June 30, 2003 for
          the purpose of preparing these pro-forma financial statements.








                                       F-5
<PAGE>



SINOVAC BIOTECH LTD.
--------------------
(formerly Net-Force Systems Inc.)

Notes to Pro-forma Consolidated Financial Statements
June 30, 2003
(Unaudited - Prepared by Management)
(Expressed in U.S. Dollars)
================================================================================


2.   Proposed Acquisition and Pro-forma Assumptions (continued)
---------------------------------------------------

     (c)  Additional Capital Financing

          Tangshan  Yian agreed to raise an  approximately  $2.6 Million  equity
          ($760,000 cash and $1,793,996 promissory note) from an unrelated party
          immediately  before  the  afore-mentioned   proposed   acquisition  by
          Sinovac.  The promissory note is secured,  bearing  interest at 8% per
          annum and has a one year term. The additional equity financing and the
          conversion of debt for equity as described in Note 2(d) will cause the
          change of control in Tangshan Yian.

          The  approximate  $2.6 Million equity capital  financing is assumed to
          have taken effect on June 30, 2003 for the purpose of preparing  these
          pro-forma financial statements.

     (d)  Debt Exchange for Shares

          Creditors of Tangshan  Yian have agreed to convert  $1,119,324 of debt
          into  equity  in  Tangshan   Yian   before  the   completion   of  the
          afore-mentioned proposed acquisition by Sinovac.

          The  proposed  debt for the equity is assumed to have taken  effect on
          June 30, 2003 for the purpose of preparing these  pro-forma  financial
          statements.

     (e)  The net assets acquired by Sinovac are summarized as follows:

          Cash and cash equivalents                          $        777,263
          Accounts receivable and others                               28,785
          Promissory note - secured and 8% interest rate            1,793,996
          Due from a related party                                  1,800,000
          Inventories                                                  81,475
          Property, Plant and equipment                             1,894,958
          Accounts payable and accrued liabilities                 (1,383,477)
          Unamortized finance charge                                 (133,000)
          ---------------------------------------------------------------------

                                                             $      4,860,000
          =====================================================================














                                       F-6
<PAGE>



SINOVAC BIOTECH LTD.
--------------------
(formerly Net-Force Systems Inc.)

Notes to Pro-forma Consolidated Financial Statements
June 30, 2003
(Unaudited - Prepared by Management)
(Expressed in U.S. Dollars)
================================================================================


3.   Pro-forma Adjustments
--------------------------

     (a)  To record the proposed  approximate  additional  $2.6  Million  equity
          financing by Tangshan Yian.

     (b)  To record the  disposal  of  investment  in China  Sinovac by Tangshan
          Yian.

     (c)  To record the  conversion of $1,119,324 of debt for equity by Tangshan
          Yian.

     (d)  To record the acquisition of Tangshan Yian by Sinovac.

     (e)  To eliminate inter-company receivable and payable.


































                                       F-7


</TEXT>
</DOCUMENT>
